Global Survey and Documentary Film Expose Emotional Impact of Multiple Sclerosis
- Merck KGaA, Darmstadt, Germany-sponsored survey developed in collaboration with IACO and Eurocarers reveals lifelong effects of caring for a loved one with MS
- #MSInsideOut documentary film, executively produced by Shift.ms, provides artistic take on the experiences of those impacted by MS
Darmstadt, Germany, October 11, 2018 – Merck KGaA, Darmstadt, Germany today announced the publication of results from a global Company-sponsored multiple sclerosis (MS) carer survey, as well as the première of the #MSInsideOut documentary, Seeing MS from the Inside Out, executive produced by Shift.ms, a social network for people with multiple sclerosis, at the 34th Congress of the European Committee for Treatment and Research In Multiple Sclerosis (ECTRIMS), in Berlin, Germany.
The ‘Living with Multiple Sclerosis: The Carer’s Perspective’ report was developed in collaboration with The International Alliance of Carer Organizations (IACO) and Eurocarers to examine the experiences of 1,050 multiple sclerosis (MS) carers across seven countries (US, Canada, UK, France, Germany, Italy and Spain). The survey found that almost half (48%) of those surveyed became MS carers when they were below the age of 35, and nearly one in three had been caring for somebody for 11 years or more.
Additional key findings from the carer survey included:
- 43% and 28% of carers surveyed reported an impact on their emotional/mental health and physical health respectively
- 34% said being an MS carer impacted their financial situation, more than a third (36%) stated they had to take time off work, and as a result, 84% of those carers reported their work and career being impacted
- Only 15% of carers surveyed connected with other carers or patient organizations to help cope with the challenges of their role
“MS can be a devastating disease for both patients and carers, with the responsibilities assumed by carers over an extended length of time and intensifying as the disease progresses. Carers can experience a profound impact on their physical and emotional health, finances, and employment,” said Nadine Henningsen, Board Chair, IACO. “Not surprisingly, the survey results reinforced the large number of young people who are becoming carers – often in a formative time of their life.”
As part of the #MSInsideOut campaign, an initiative aimed at providing a deeper understanding of MS, the MS Inside Out documentary film, ‘Seeing MS from the Inside Out’, will be premièred. Developed with Shift.ms as executive producers, it is the first global documentary film to pair artists and people from across the MS community, with a view to interpreting the experiences and perspectives of those impacted by MS through art.
“In line with our broader mission at Shift.ms, the aim of this documentary is to highlight the individual stories in a unique and innovative way across the MS community, digging deeper into the elements of MS that remain under-represented with a view of interpreting the unmet needs of those impacted by MS through art,” said George Pepper, Co-founder and CEO, Shift.ms. “By bringing these stories out into the open we will be able to address those challenges that remain, opening lines of communication and ultimately raising awareness of MS.”
The documentary follows three stories: Maria Florencia, a person living with MS from Argentina, Jon Strum, a caregiver from the US, and Dr. Luigi Lavorgna, a healthcare professional from Italy. Each were paired with a local visual artist to bring their stories to life through an emotional interpretation not bound by words but through art, reflecting the often difficult-to-explain nature of MS.
The premiere will take place at 12:00 – 1:30 pm EST today on October 11, during ECTRIMS 2018 and can be accessed through a livestream link here: http://www.touch-stream.com/MSinsideout.
“We are extremely proud to highlight the unmet needs in the community through our work with Shift.ms, IACO and Eurocarers which expose the experiences of different members of the MS community, including the perspective of MS carers, whose voices have traditionally not been heard as strongly,” said Andrew Paterson, Senior Vice President, Global Head of Neurology and Immunology, at the biopharma business of Merck KGaA, Darmstadt, Germany. “Forming part of our ongoing company-wide commitment to carers, and connecting with the broader Embracing Carers initiative, the outcomes from both the survey and documentary film highlight the need for additional support and awareness. We therefore encourage and call upon the MS community to take these findings and identify ways in which they can better assist both MS carers and patients.”
All Merck KGaA, Darmstadt, Germany, press releases are distributed by e-mail at the same time they become available on the EMD Group Website. In case you are a resident of the USA or Canada please go to www.emdgroup.com/subscribe to register for your online subscription of this service as our geo-targeting requires new links in the email. You may later change your selection or discontinue this service.
About Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across life science, healthcare and electronics. Around 60,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2021, Merck KGaA, Darmstadt, Germany, generated sales of € 19.7 billion in 66 countries.
The company holds the global rights to the name and trademark “Merck” internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany, operate as MilliporeSigma in life science, EMD Serono in healthcare, and EMD Electronics in electronics. Since its founding in 1668, scientific exploration and responsible entrepreneurship have been key to the company’s technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company.
Merck KGaA, Darmstadt, Germany, has acquired Massachusetts-based Erbi Biosystems, a developer of the 2 ml micro-bioreactor platform technology, known as the “Breez™”.